High-density lipoprotein (HDL) transport in the metabolic syndrome: Application of a new model for HDL particle kinetics

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 3, 2006, Pages 973-979

  Ji, Juying ^a   Watts, Gerald F ^a,g   Johnson, Anthony G ^b   Chan, Dick C ^a   Ooi, Esther M M ^a   Rye, Kerry Anne ^c,d,e   Serone, Adrian P ^f   Barrett, P Hugh R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b GLAXOSMITHKLINE   (United States)

^c HEART RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f PRINCE OF WALES HOSPITAL   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; HIGH DENSITY LIPOPROTEIN; LEUCINE;

ARTICLE; CARDIOVASCULAR RISK; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GAS CHROMATOGRAPHY; GENE ACTIVITY; HIGH RISK PATIENT; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MALE; MASS SPECTROMETRY; METABOLIC SYNDROME X; MODEL; OBESITY; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; WAIST CIRCUMFERENCE;

APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; HUMANS; KINETICS; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; REFERENCE VALUES;

EID: 33644822084     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1895     Document Type: Article

References (39)

1. Ford ES 2004 Prevalence of the metabolic syndrome in US populations. Endocrinol Metab Clin North Am 33:333-350
2. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS 2004 Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation 109:42-46
3. von Eckardstein A, Nofer JR, Assmann G 2001 High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21:13-27
4. Tailleux A, Duriez P, Fruchart JC, Clavey V 2002 Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis 164:1-13
5. Schaefer EJ, Ordovas JM 1986 Metabolism of apolipoproteins A-I, A-II, and A-IV. Methods Enzymol 129:420-443
6. Brinton EA, Eisenberg S, Breslow JL 1989 Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J Clin Invest 84:262-269
7. Ikewaki K, Zech LA, Kindt M, Brewer Jr HB, Rader DJ 1995 Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans. Arterioscler Thromb Vasc Biol 15:306-312
8. Cheung MC, Albers JJ 1982 Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J Lipid Res 23:747-753
9. Borggreve SE, De Vries R, Dullaart RP 2003 Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 33:1051-1069
10. Huang Y, von Eckardstein A, Wu S, Assmann G 1995 Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol 15:1412-1418
11. Syvanne M, Kahri J, Virtanen KS, Taskinen MR 1995 HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus. Circulation 92:364-370
12. Pietzsch J, Julius U, Nitzsche S, Hanefeld M 1998 In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 47:1928-1934
13. Frenais R, Nazih H, Ouguerram K, Maugeais C, Zair Y, Bard JM, Charbonnel B, Magot T, Krempf M 2001 In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus. J Clin Endocrinol Metab 86:1962-1967
14. Brinton EA, Eisenberg S, Breslow JL 1994 Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 14:707-720
15. Duvillard L, Pont F, Florentin E, Gambert P, Verges B 2000 Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in noninsulin-dependent diabetes mellitus. Atherosclerosis 152:229-237
16. Terry RB, Yurgalevitch S, Thompson PD 1992 High-density apolipoprotein A-I and A-II kinetics in relation to regional adiposity. Metabolism 41:1386-1392
17. Vajo Z, Terry JG, Brinton EA 2002 Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women. Atherosclerosis 160:495-501
18. Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG 2003 Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 52:803-811
19. Zech LA, Schaefer EJ, Bronzert TJ, Aamodt RL, Brewer HB 1983 Metabolism of human apolipoproeins A-I and A-II: compartment models. J Lipid Res 24:60-71
20. Rader DJ, Castro G, Zech LA, Fruchart JC, Brewer Jr HB 1991 In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I,A-II. J Lipid Res 32:1849-1859
21. Tilly-Kiesi M, Lichtenstein AH, Joven J, Vilella E, Carrasco WV, Ordovas JM, Dolnikowski G, Schaefer EJ 1997 Impact of gender on the metabolism of apolipoprotien A-I in HDL subclasses LpAI and LpAI:AII in older subjects. Arterioscler Thromb Vasc Biol 17:3513-3518
22. Parra HJ, Mezdour H, Ghalim N, Bard JM, Fruchart JC 1990 Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem 36:1431-1435
23. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE 2003 Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459-469
24. Barter P 2004 Metabolic abnormalities: high-density lipoproteins. Endocrinol Metab Clin North Am 33:393-403
25. Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R, Ginsberg HN 1993 Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 91:1743-1752
26. Kaser S, Sandhofer A, Foger B, Ebenbichler CF, Igelseder B, Malaimare L, Paulweber B, Patsch JR 2001 Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 44:1111-1117
27. Jonkers IJ, Smelt AH, Hattori H, Scheek LM, van Gent T, de Man FH, van der Laarse A, van Tol A 2003 Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. J Lipid Res 44:1462-1469
28. Fruchart JC, Duriez P, Staels B 1999 Peroxisome proliferator-activated receptor-α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10:245-257
29. Van Tol A 2002 Phospholipid transfer protein. Curr Opin Lipidol 13:135-139
30. Qin S, Kawano K, Bruce C, Lin M, Bisgaier C, Tall AR, Jiang XC 2000 Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. J Lipid Res 41:269-276
31. Pussinen PJ, Jauhiainen M, Ehnholm C 1997 ApoA-II/apoA-I molar ratio in the HDL particle influences phospholipid transfer protein-mediated HDL interconversion. J Lipid Res 38:12-21
32. Lewis GF, Rader DJ 2005 New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96:1221-1232
33. Rye KA, Barter PJ 2004 Formation and metabolism of pre-β-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 24:421-428
34. Luc G, Bard JM, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P, on behalf of the PRIME Study Group 2002 Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease. The PRIME Study. Arterioscler Thromb Vasc Biol 22:1155-1161
35. Syvanne M, Castro G, Dengremont C, De Geitere C, Jauhiainen M, Ehnholm C, Michelagnoli S, Franceschini G, Kahri J, Taskinen MR 1996 Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis 127:245-253
36. Ohta T, Hattori S, Nishiyama S, Matsuda I 1998 Studies on the lipid and apolipoprotein compositions of two species of apoA-I containing lipoproteins in normolipidemic males and females. J Lipid Res 29:721-728
37. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM 2004 Antiinflammatory properties of HDL. Circ Res 95:764-772
38. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R 1998 Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 273:6088-6095
39. Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Dzavik V, Fruchart JC, Fievet C, Lefebvre P, Staels B 2005 Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferators-activated receptor-α modulation. Arterioscler Thromb Vasc Biol 25:585-591